SCHEMBL4169551

SCHEMBL4169551

Cc1ccc2c(c1)C1(NC(=O)NC1=O)C(=O)N2CCc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.51
MAPT P10636 6/20 0.51
PARK7 Q99497 1/20 0.46
TP53 P04637 6/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
ADAMTS5 Q9UNA0 2/20 0.43
USP2 O75604 4/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
LMNA P02545 2/20 0.42
CNR1 P21554 1/20 0.41
ALOX15 P16050 2/20 0.41
TSHR P16473 1/20 0.41
CASP1 P29466 1/20 0.40
HSD17B10 Q99714 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
AKR1B1 P15121 1/20 0.39
GAA P10253 1/20 0.38
HPGD P15428 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4259885 0.88 ADAMTS5 (0.52) ALDH1A1MAPTTP53SMN1; SMN2ADAMTS5
SCHEMBL4164986 0.86 PARK7 (0.64) ALDH1A1MAPTPARK7TP53CNR1
SCHEMBL4164476 0.86 CNR1 (0.51) ALDH1A1MAPTPARK7TP53SMN1; SMN2
SCHEMBL4170549 0.84 ALDH1A1 (0.52) ALDH1A1MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL4167713 0.83 AKR1B1 (0.40) ALDH1A1MAPTSMN1; SMN2ADAMTS5MEN1
SCHEMBL4167006 0.81 MAPT (0.47) ALDH1A1MAPTTP53MEN1KMT2A
SCHEMBL4255427 0.81 MAPT (0.45) ALDH1A1MAPTTP53SMN1; SMN2MEN1
SCHEMBL4254388 0.81 AKR1B1 (0.41) ALDH1A1MAPTSMN1; SMN2LMNACNR1
SCHEMBL4164829 0.81 AKR1B1 (0.41) ALDH1A1MAPTSMN1; SMN2ADAMTS5MEN1
SCHEMBL4260196 0.80 MEN1 (0.51) ALDH1A1MAPTTP53SMN1; SMN2ADAMTS5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090076049-A1 Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 ASTRAZENECA AB (SE) 2009-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090076049-A1 Novel Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 TRPV1, TRPV5, TRPV2 ALDH1A1 550/4885MAPT 2775/4885PARK7 1295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.